RAF1 and left ventricular hypertrophy: This left ventricular hypertrophy was associated with PDGF-BB and TGFß1 overexpression, as well as with phosphorylation of their c-raf and ERK1/2 signaling pathways, all of which were downregulated by sorafenib treatment.